Trade IDEXX Laboratories, Inc. - IDXX CFD

Trading Conditions
Spread0.49
Long position overnight fee
Long position overnight fee

Margin. Your investment
US$1,000.00
Overnight fee
Charges from full value of position
-0.026179 %
(-US$1.05)

Trade size with leverage ~ US$5,000.00

Short position overnight fee ~ US$4,000.00


-0.026179%
Short position overnight fee
Short position overnight fee

Margin. Your investment
US$1,000.00
Overnight fee
Charges from full value of position
0.003957 %
(US$0.16)

Trade size with leverage ~ US$5,000.00

Short position overnight fee ~ US$4,000.00


0.003957%
Overnight fee time21:00 (UTC)
CurrencyUSD
Min traded quantity1
Margin20
Stock exchangeUnited States of America
Commission on trade10%

Information_provided_by_capital
1Our charge for executing your trade is the spread, the difference between the buy and sell price. Please consult the Charges and Fees section of our website for further information

Key Stats
Prev. Close489.1
Open486.57
1-Year Change0.78%
Day's Range486.57 - 498.45

IDEXX Labs Company profile

About IDEXX Laboratories, Inc.

IDEXX Laboratories, Inc. develops, manufactures and distributes products and provides services for the companion animal veterinary, livestock and poultry, dairy and water testing markets. It also sells a line of portable electrolytes and blood gas analyzers used in the human diagnostics market. Its segments include Companion Animal Group (CAG), Water quality products (Water), and Livestock, Poultry and Dairy (LPD). The CAG segment CAG develops, designs, manufactures, and distributes products and performs services for veterinarians and the biomedical analytics market, primarily related to diagnostics and information management. The Water segment develops, designs, manufactures, and distributes a range of products used in the detection of various microbiological parameters in water. The LPD segment develops, designs, manufactures, and distributes diagnostic tests and related instrumentation and performs services that are used to manage the health status of livestock and poultry.

Financial summary

BRIEF: For the fiscal year ended 31 December 2021, IDEXX Laboratories, Inc. revenues increased 19% to $3.22B. Net income increased 28% to $744.8M. Revenues reflect CAG segment increase of 21% to $5.42B, Water segment increase of 14% to $146.5M, United States segment increase of 18% to $2B, Canada segment increase of 30% to $139.7M, Germany segment increase of 23% to $146.8M. Net income benefited from CAG segment income increase of 43% to $824M.

Equity composition

Common Stock $.10 Par, 06/11, 120M auth., 98,835,000 issd., less 42,004,000 shs. in Treas. @ $1.16B. Insiders control approx.1.09%. IPO: 4/92, 1.5M shares @ $20.50 by Lehman Brothers. PO: 10/95, 4.6M shares @ $35 by Cowen & Company. 11/07, 6/95 & 10/93, 2-for-1 stock splits. 06/15, 2-for-1, Stock Split.